IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 4248 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded265    
    Comments [Add]    

Recommend this journal


Year : 1998  |  Volume : 30  |  Issue : 6  |  Page : 367-378

Pharmacotherapy of male erectile dysfunction with sildenafil

Correspondence Address:
S K Kulkarni

Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Male erectile dysfunction (MED) is a common sexual disorder influenced by psychological, organic, physical, endocrine and neurovascular factors. Parasympathetic stimulation activates cholinergic receptors resulting in increased production of nitric oxide and vasoactive peptides which increase the cyclic guanosine monophosphate (cGMP) and thereby increasing vascular smooth muscle relaxation and vasodilation of corpus cavernosum.This causes rigid penile erection sufficient for sexual intercourse. However, in erectile dysfunction, there is an inability to achieve or maintain a penile erection. One of the current approaches in therapies for MED includes elevating levels of cGMP using phosphodiesterase (PDE) inhibitors. Sitdenafil is the first orally active, potent and competitive inhibitor of type-5 cGMP specific PDE enzyme that has been recently approved for the treatment of MED. Sildenafil is a synthetic methylpiperazine derivative that selectively inhibits PDE in human corpus cavernosum. Sildenafil has demonstrated its effectiveness in erectile dysfunction in several preclinical and clinical studies. It is well-tolerated (50-100 mg/day, p.o.) and safe agent for erectile dysfunction in patients with diabetes, traumatic spinal cord injury, psychological causes and physiological disorders. Adverse events reported include transient headache, dyspepsia, flushing, diarrhea and visual disturbance. The discovery of sildenafil has not only resulted in a huge market for drugs, but also unfolded the pathophysiology of erectile dysfunction. However, more controlled clinical studies are needed to establish the safety of sildenafil in patients with different age groups.


Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow